The DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index.
The role of PARP in DNA repair and its therapeutic exploitation
Open accessAbstract
Historically, PARP inhibitors (PARPi) were developed to potentiate the cytotoxic effect of certain chemotherapeutic agents and are currently being investigated in combination with chemotherapy in diverse cancer types. These agents are also radiosensitisers and clinical trials of PARPi with concurrent radiation are required. It has long been recognised that defective DNA repair pathways lead to tumour susceptibility. Recent studies indicate that tumour cells with defective homologous recombination (HR) repair pathways, the classic example being BRCA mutations, are exquisitely sensitive to PARPi. Defects in HR are not restricted to BRCA-associated tumours and other cancer types may be enriched for HR defects and hence susceptible to PARP inhibition. The identification of predictive markers for sensitivity to PARP inhibition is a priority area for research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–220 of 220
Barrows, L. R., Holden, J. A., Anderson, M., & D’Arpa, P. (1998) · Mutation Research/DNA Repair · doi:10.1016/s0921-8777(98)00022-6 · Cited by 58
Cousineau, I., & Belmaaza, A. (2011) · Molecular Genetics and Genomics · doi:10.1007/s00438-011-0612-5 · Cited by 57
Daniel, R. A., Rozanska, A. L., Mulligan, E. A., Drew, Y., Thomas, H. D., Castelbuono, D. J., Hostomský, Z., Plummer, E. R., Tweddle, D. A., Boddy, A. V., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605946 · Cited by 57
Self-citationAli, M., Telfer, B. A., McCrudden, C. M., O’Rourke, M., Thomas, H. D., Kamjoo, M., Kyle, S., Robson, T., Shaw, C., Hirst, D. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0398 · Cited by 56
Self-citationMitchell, J., Smith, G. C. M., & Curtin, N. J. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.1722 · Cited by 54
Self-citationTentori, L., Turriziani, M., Franco, D., Serafino, A., Levati, L., Roy, R., Bonmassar, E., & Graziani, G. (1999) · Leukemia · doi:10.1038/sj.leu.2401423 · Cited by 54
Mahany, J. J., Lewis, N., Heath, E. I., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3579 · Cited by 51
Arundel-Suto, C. M., Scavone, S. V., Turner, W. R., Suto, M. J., & Sebolt, J. S. (1991) · PubMed · Cited by 47
Guggenheim, E. R., Ondrus, A. E., Movassaghi, M., & Lippard, S. J. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.09.074 · Cited by 47
Methylation profiles of hereditary and sporadic ovarian cancer
Bol, G. M., Suijkerbuijk, K. P. M., Bart, J., Vooijs, M., van der Wall, E., & van Diest, P. J. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03642.x · Cited by 47
Weichselbaum, R. R., & Little, J. B. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.237 · Cited by 45
Human Nuclear NAD + ADP-Ribosyltransferase(polymerizing): Organization of the Gene
Auer, B., Nagl, U. O., Herzog, H., Schneider, R., & Schweiger, M. (1989) · DNA · doi:10.1089/dna.1989.8.575 · Cited by 39
Tentori, L., Portarena, I., Barbarino, M., Balduzzi, A., Levati, L., Vergati, M., Biroccio, A., Gold, B. I., Lombardi, M. L., & Graziani, G. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.1.192 · Cited by 39
Giaccone, G., Rajan, A., Kelly, R. J., Gutierrez, M. E., Kummar, S., Yancey, M. F., Ji, J., Zhang, Y., Parchment, R. E., & Doroshow, J. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3027 · Cited by 37
Histone shuttle driven by the automodification cycle of poly(ADP‐ribose) polymerase
Althaus, F. R., Höfferer, L., Kleczkowska, H. E., Malanga, M., Naegeli, H., Panzeter, P. L., & Realini, C. A. (1993) · Environmental and Molecular Mutagenesis · doi:10.1002/em.2850220417 · Cited by 36
DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer
Alexander, B. M., Sprott, K. M., Farrow, D. A., Wang, X., D’Andrea, A. D., Schnitt, S. J., Collins, L. C., Weaver, D. T., & Garber, J. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0292 · Cited by 35
Bernges, F., & Zeller, W. J. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01209029 · Cited by 31
Therapeutic potential of drugs to modulate DNA repair in cancer
Curtin, N. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.6.783 · Cited by 27
Self-citationLiu, H., Knabb, J. R., Spike, B. T., & Macleod, K. F. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0439 · Cited by 21
Bauer, P. I., Mendeleyeva, J., Kirsten, E., Comstock, J. A., Hakam, A., Büki, K. G., & Kun, E. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00872-3 · Cited by 20
Cited by
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
De Vos, M., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 492
DNA repair targeted therapy: The past or future of cancer treatment?
Gavande, N. S., VanderVere-Carozza, P. S., Hinshaw, H. D., Jalal, S. I., Sears, C. R., Pawelczak, K. S., & Turchi, J. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.003 · Cited by 387
Oxidatively induced DNA damage and its repair in cancer
Dizdaroglu, M. (2015) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.11.002 · Cited by 254
Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers
Buckley, A. M., Lynam-Lennon, N., O’Neill, H., & O’Sullivan, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0247-2 · Cited by 254
Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes
Cantó, C., Sauve, A. A., & Bai, P. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.004 · Cited by 246
Metadata
- Authors
- Javle, M., & Curtin, N. J.
- Venue
- British Journal of Cancer
- Published
- 2011-10
- Volume
- 105
- Issue
- 8
- Pages
- 1114-1122
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2124092811
- Cited by
- 320
- References
- 220
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.